Hyperion Therapeutics Secures $60,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=af8f0933-a62f-4ed1-b122-996ac77d3737&Preview=1 -
Date
7/5/2009 -
Company Name
Hyperion Therapeutics -
Mailing Address
601 Gateway Blvd South San Francisco, CA 94080 -
Company Description
Hyperion Therapeutics, Inc. is a privately held specialty biopharmaceutical company dedicated to improving patients’ lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company’s initial efforts are focused in the areas of gastroenterology and hepatology. -
Website
http://www.hyperiontx.com -
Transaction Type
Venture Equity -
Transaction Amount
$60,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The capital will fund the Phase III clinical program for UCD as well as a Phase II study in low grade hepatic encephalopathy. -
M&A Terms
-
Venture Investor
Bay City Capital -
Venture Investor
Panorama Capital -
Venture Investor
Highland Capital Partners -
Venture Investor
New Enterprise Associates -
Venture Investor
Sofinnova Ventures
